Serum Anti-Gal-3 Autoantibody is a Predictive Marker of the Efficacy of Platinum-Based Chemotherapy against Pulmonary Adenocarcinoma

Abstract

Background: Identification of predictive markers for the efficacy of platinum-based chemotherapy is necessary to improve the quality of the life of cancer patients. Materials and Methods: We detected proteins recognized by autoantibodies in pretreated sera from patients with lung adenocarcinoma (AC) evaluated as showing progressive disease (PD) or a partial response (PR) after cisplatin-based chemotherapy by proteomic analysis. Then, the levels of the candidate autoantibodies in the pretreated serum were validated by dot-blot analysis for 22 AC patients who received platinum-based chemotherapy, and the expression of identified proteins was immunohistochemically analyzed in 40 AC biopsy specimens. Results: An autoantibody against galectin-3 (Gal-3) was detected in pretreated sera from an AC patient with PD. Serum IgG levels of anti-Gal-3 autoantibody were significantly higher in patients evaluated with PD than in those with PR and stable disease (SD) (p = 0.0084). Furthermore, pretreated biopsy specimens taken from patients evaluated as showing PD following platinumbased chemotherapy showed a tendency to have a higher positive rate of Gal-3 than those with PR and SD (p = 0.0601). Conclusions: These results suggest that serum IgG levels of anti-Gal-3 autoantibody may be useful to predict the efficacy of platinum-based chemotherapy for patients with lung AC.

Prognostic significance of galectin‐3 expression in patients with resected NSCLC treated with platinum‐based adjuvant chemotherapy

“…In addition, GAL3 induces chemoresistance by regulating apoptotic activity through phosphorylation and translocation of GAL3, regulation of mitochondrial membrane potential, and regulation of cell survival and caspase pathways 15 . Further, we previously reported that serum anti‐GAL3 autoantibody levels effectively predicted the efficacy of platinum‐based chemotherapy for advanced NSCLC 16 . However, no study has investigated the efficacy of GAL3 as a predictor of AC efficacy in patients with resected NSCLC.…”

“…15 Further, we previously reported that serum anti-GAL3 autoantibody levels effectively predicted the efficacy of platinumbased chemotherapy for advanced NSCLC. 16 However, no study has investigated the efficacy of GAL3 as a predictor of AC efficacy in patients with resected NSCLC. Therefore, this study aimed to analyze the association of GAL3 expression with the clinicopathological characteristics and prognosis of patients with surgically resected stages II and IIIA NSCLC and administered adjuvant chemotherapy.…”

Autoantibodies as diagnostic biomarkers for lung cancer: A systematic review

“…The titles and abstracts of 7173 articles were screened and a total of 7079 were excluded based on the exclusion criteria described above. Of the remaining 94 full-text articles, 10 were excluded because a disease control was used 14–23 , 9 were excluded because they did not have satisfied outcomes 24–32 , and 8 were excluded because of their small sample size ( n < 10) 33–40 , Ultimately, 67 articles were included in this systematic review evaluating the diagnostic performance of TAAbs in serum or plasma for LC detection (Tables 1 and 2).…”

The crossroads between cancer immunity and autoimmunity antibodies to self antigens

“…Anti-AFP, -Gankyrin, -GPC-3, -IMP1, -p62, -Koc, -p53, -c-Myc, -Cyclin-B1, -HuD, -Survivin, -MAGEA4, -p16, -SOX-2, -CAGE, -NY-ESO-1, -GBU4-5 of autoantibodies against galectin-3 could be useful to predict the efficacy of chemotherapy in patients with lung adenocarcinoma (230).…”